Crecheck not checked

Hanlim Pharm. Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
12 active
16 in total · 15 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Primary Hypercholesterolemia, Combined Hyperlipidemia
Main trialPhase 1
“This clinical trial is an open, randomized, 2-group, 2-period, fasting, single-dose, crossover study to evaluate the bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" of Hanlim Pharm. Co., Ltd. and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" of AstraZeneca Korea Co., Ltd. in healthy adult subjects.”In the company’s words, NCT06475872 on ClinicalTrials.gov
Other names
Rosuvastatin Calcium
Copy of
Crestor (Astrazeneca)Tested side by side with the original in NCT06475872

Other drugs for Primary Hypercholesterolemia

All 21 drugs for Primary Hypercholesterolemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 1Completed 7 Dec 2023 Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects
Phase 3Authorised not given StAtins for Venous Event Reduction in Patients with Venous Thromboembolism : The SAVER Trial
Phase 3/4Ended not given Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia – LEASH
Phase 1Ended not given Randomized, open-label, single dose, four-period, cross-over drug-drug interaction study comparing reference products Crestor 20 mg film coated tablets, Norvasc 10 mg tablets and Tritace 10 mg tablets administrated concomitantly versus each drug administrated alone in healthy male and female subjects under fasting conditions. Sponsor's study number: ROS-AML-RAM-DDI-03-23
Phase 4Authorised not given Pragmatic clinical trial to assess the utility of SLCO1B1, ABCG2, and CYP2C9 preepmtive genotyping and pharmacogenetics training on the incidence of musculoskeletal adverse reactions in patients treated with statins in primary and specialized care.
Phase 1Ended not given An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects
Phase 4Authorised not given N=1-studies In Statin-intolerance; Objectifying Nocebo Effects (NISONE)
Phase 4Authorised not given A multicentre controlled, randomised, single-blind adaptive phase IV protocol to evaluate efficacy, safety and cost-efficacy of pre-emptive genotyping strategy in a population at risk of cardiovascular disease susceptible of receiving high or moderate-intensity doses of statins
Phase 4Authorised not given The Pragmatic EE-PRS Trial assessing Polygenic Risk Driven Statin Therapy for Cardiovascular Disease Prevention
Phase 3Authorised not given Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head PICOLO-FH clinical trial
Phase 4Authorised not given The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis
Phase 4Authorised not given StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial
Phase 3Authorised not given EUROpean pragmatic multicenter randomized trial on platelet inhibition and/or lipid lowering treatment in Covert Brain Infarction (CBI)
Phase 2/3Authorised not given Changes in plaque characteristics after short-term statin therapy assessed with coronary CT
Phase 3/4Authorised not given Self-Assessment Method for Statin side-effects Or Nocebo 2
Phase 4Authorised not given Early LDL -cholesterol reduction in patients with acute coronary syndrome: a randomized clinical trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Crecheck

Following is part of Solo: you see every change to Crecheck the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in